

SENISCA is an RNA therapeutics spinout from the University of Exeter. Our founders are world leaders in the molecular biology of ageing and have patent-protected a new innovation for the reversal of cellular senescence.

This innovation works by restoring the ability of cells to 'fine tune' the expression of their genes to rejuvenate aged cells.

At SENISCA, we will use this patent-protective knowledge, about how and why cells become senescent, to develop a new generation of oligonucleotide-based interventions, to turn back the ageing clock in old cells and to target the diseases and aesthetic signs of ageing.

Scientific Advisory Board Expansion

Location:	Exeter or on-line meetings
Start Date:	Summer 2022, meeting quarterly

SENISCA is seeking to expand its Scientific Advisory Board [SAB] with 3 new members. SAB members will be expected to attend quarterly meetings to support SENISCA's Chief Scientific Officer and Executive team across each R&D division of the business. Meetings will be either in-person at SENISCA's Exeter UK-based R&D lab facilities or on-line via Zoom.

We are looking for either academic, biotech or pharmaceutical sector individuals with the following experience. Our aim is that at least 2 of the 3 candidates will have an oligonucleotide drug development background:

- A track record of accomplishments in leading drug discovery teams from target identification through delivery of clinical candidates and establishing clinical translational strategy.
- Expertise (scientifically or commercially) in an area of oligonucleotide therapeutics, or within any of the broad range of age-related disease(s) targeted by SENISCA's platform technology.
- Expertise in oligonucleotide synthesis and chemical modification.
- Expertise in oligonucleotide cell delivery technology.

Apply

Please send CV's and initial enquiries to HR@senisca.com addressed to Anna Bennett (SENISCA's business co-ordinator), within the initial application window of the 15th February to 15th of March 2022. We look forward greatly to hearing from you.